Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

Jan 11, 2021 9:00am EST

CohBar Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

Dec 09, 2020 9:00am EST

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

Nov 19, 2020 9:00am EST

CohBar to Present at the Piper Sandler 32nd Annual Healthcare Conference

Nov 16, 2020 4:01pm EST

CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update

Nov 02, 2020 9:00am EST

CohBar to Announce 2020 Third Quarter Financial Results and Provide Business Update on November 16, 2020

Oct 29, 2020 9:00am EDT

CohBar to Host Key Opinion Leader Meeting on Antifibrotic Peptides for the Potential Treatment of Idiopathic Pulmonary Fibrosis

Oct 27, 2020 9:00am EDT

CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event

Oct 26, 2020 9:00am EDT

CohBar Antifibrotic Peptide in Combination with Nintedanib Shows Enhanced Effects in an Idiopathic Pulmonary Fibrosis Model

Oct 15, 2020 4:05pm EDT

CohBar to Present at the BIO-Europe Conference

Oct 08, 2020 9:00am EDT

CohBar’s CEO to Participate on the Emerging Companies Panel at the Targeting Metabesity Conference